Abstract
Although oxaliplatin is one of the main anticancer agents used against colorectal cancer, data on the pharmacokinetics of oxaliplatin in patients on hemodialysis are limited. In this case study, we evaluated the pharmacokinetics and safety of oxaliplatin in a patient on hemodialysis treated for colon cancer.
Highlights
The number of patients with end-stage renal disease is increasing rapidly worldwide
Modified FOLFOX6 plus bevacizumab every 2 weeks could be safely given in a hemodialytic colon cancer patient with a reduction in oxaliplatin dose to 50 mg/m2, if hemodialysis was performed 1.5 hours after the end of oxaliplatin infusion
After a slight increase caused by free platinum moving from tissue to blood, it decreased from the start to the completion of hemodialysis, increased up to 24 hours and maintained a plateau thereafter
Summary
The number of patients with end-stage renal disease is increasing rapidly worldwide. These patients require dialysis treatment or renal transplantation for survival [1]. Standard treatments for primary chemotherapy include the addition of a molecular-targeted agent to oxaliplatin- or irinotecan-based chemotherapy, and mean survival time in patients with recurrent or metastatic colorectal cancer has improved to over 30 months [7,8]. One report noted that a dose reduction is not necessary if creatinine clearance is more than 20 mL/min [10], it is not clear whether oxaliplatin can be administered in patients with severe renal dysfunction or hemodialysis. We evaluated the pharmacokinetics and safety of oxaliplatin in a patient on hemodialysis treated for colon cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
